A new report suggests targeting the Gal9/TIM3-axis could help boost chances of complete remission in patients with acute myeloid leukemia.
Acute Myeloid Leukemia
With the exception of bladder cancer, the frequency of KDM6A gene mutations in malignancy is thought to be rather low in malignant developments.
A new suggests that the gene expression signature 4-GES, which consists of four genes (SOCS2, IL2RA, NPDC1, PHGDH), may be an independent prognostic factor in acute myeloid leukemia (AML).
The addition of sorafenib to intensive chemotherapy had a significant impact on the survival rate of patients with FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
This article summarizes available data for the use of CYP3A4 inhibitors with midostaurin for acute myeloid leukemia.
Early data on the safety and tolerability of combination venetoclax and cytarabine or cytarabine/idarubicin were presented at ASCO 2019.
Background: Acute myeloid leukemia (AML) is a malignancy of the bone marrow in which development of hematopoietic precursors halts during early stages of marrow formation.
A randomized phase II trial investigated whether adding CX-01, a low anticoagulant heparin derivative, to standard care improves outcomes in older patients with acute myeloid leukemia.
The survival benefit observed with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia in the ADMIRAL trial was maintained regardless of the presence of several common co-mutations.
Data were presented at ASCO 2019 on the link between current and former smoking on treatment outcomes in AML in treatment-naive patients.